TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer
January 12 2022 - 6:45AM
TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell
therapy company with a pipeline of novel T cell therapies for
patients suffering from solid tumors, today announced the
appointment of Rosemary Harrison, Ph.D., as Chief Business and
Strategy Officer where she will be responsible for supporting a
range of activities including commercial strategy, operational
planning, corporate partnerships and long-term growth
opportunities.
“We are pleased to welcome Dr. Rosemary Harrison
as our first Chief Business and Strategy Officer at TCR2 as she has
proven throughout her career an ability to work closely with
multiple commercial functions to identify and execute clear
strategic priorities,” said Garry Menzel, Ph.D., President and
Chief Executive Officer of TCR2 Therapeutics. “We look forward
to her immediate operational impact as 2022 is a year full of
milestones in which our lead program gavo-cel will enter a Phase 2
clinical trial, TC-510 will enter a Phase 1 clinical trial and
several other programs provide opportunities for strategic
dialogue.”
Dr. Harrison brings to TCR2 nearly 20 years of
global experience working on strategic planning, portfolio
management, and business development at both pharmaceutical and
biotechnology companies. Prior to joining the Company, she was
Senior Vice President of Corporate Development and Strategy at
Trillium Therapeutics where she led its acquisition by Pfizer for
$2.22 billion in November 2021. Before that, Dr. Harrison served in
strategic and research roles within RA Capital Management and as
Head of Rare Diseases at Imbria Pharmaceuticals. Earlier in her
career, she was Head of Portfolio Management and Strategic Planning
at the Novartis Institutes for Biomedical Research as well as a
consultant at Bain & Company where she advised on corporate
strategic and operational programs. Dr. Harrison holds a Bachelor
of Biotechnology in Drug Design and Development and a Ph.D. from
The University of Queensland.
“TCR2’s first-in-class T cell platform is highly
differentiated by leveraging the full TCR complex, independent of
HLA and has already demonstrated encouraging clinical data in
treatment-refractory solid tumors,” said Dr. Harrison. “I am
thrilled to be joining TCR2 during such an important period and
look forward to working with the outstanding team to focus
priorities and support a clear execution plan.”
About
TCR2
Therapeutics
TCR2 Therapeutics Inc. is a
clinical-stage cell therapy company developing a pipeline of novel
T cell therapies for patients suffering from solid
tumors. The company is focused on the discovery and
development of product candidates against novel and complex targets
utilizing its proprietary T cell receptor (TCR) Fusion
Construct T cells (TRuC®-T cells). The TRuC platform is
designed to specifically recognize and kill cancer cells by
harnessing signaling from the entire TCR, independent of human
leukocyte antigens (HLA). For more information about TCR2, please
visit www.tcr2.com.
Forward-looking
Statements
This press release contains forward-looking
statements and information within the meaning of the Private
Securities Litigation Reform Act of 1995 and other federal
securities laws. The use of words such as "may," "will," "could",
"should," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "projects," "seeks," "endeavor,"
"potential," "continue" or the negative of such words or other
similar expressions can be used to identify forward-looking
statements. These forward-looking statements include, but are not
limited to, express or implied statements regarding the therapeutic
potential of gavo-cel and TCR2’s other product candidates, timing
for interim updates for the gavo-cel clinical trial, expectations
regarding the timing of TCR2’s TC-510 IND submission and Phase 1
clinical trial initiation, expectations regarding manufacturing
plans and capabilities, future clinical development, partnering and
commercialization plans, the development of the Company’s TRuC-T
cells, their potential characteristics, applications and clinical
utility, and the potential therapeutic applications of the
Company’s TRuC-T cell platform.
The expressed or implied forward-looking
statements included in this press release are only predictions and
are subject to a number of risks, uncertainties and assumptions,
including, without limitation: uncertainties inherent in clinical
studies and in the availability and timing of data from ongoing
clinical studies; whether interim results from a clinical trial
will be predictive of the final results of the trial; whether
results from preclinical studies or earlier clinical studies will
be predictive of the results of future trials; the expected timing
of submissions for regulatory approval or review by governmental
authorities, including review under accelerated approval processes;
orphan drug designation eligibility; regulatory approvals to
conduct trials or to market products; TCR2’s ability to maintain
sufficient manufacturing capabilities to support its research,
development and commercialization efforts, including TCR2’s ability
to secure additional manufacturing facilities; whether TCR2's cash
resources will be sufficient to fund TCR2's foreseeable and
unforeseeable operating expenses and capital expenditure
requirements, the impact of the COVID- 19 pandemic on TCR2’s
ongoing operations; and other risks set forth under the caption
"Risk Factors" in TCR2’s most recent Annual Report on Form 10-K,
most recent Quarterly Report on Form 10-Q and its other filings
with the Securities and Exchange Commission. In light of these
risks, uncertainties and assumptions, the forward-looking events
and circumstances discussed in this press release may not occur and
actual results could differ materially and adversely from those
anticipated or implied in the forward-looking statements. You
should not rely upon forward- looking statements as predictions of
future events. Although TCR2 believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot guarantee that the future results, levels of activity,
performance or events and circumstances reflected in the
forward-looking statements will be achieved or occur.
Moreover, except as required by law, neither
TCR2 nor any other person assumes responsibility for the accuracy
and completeness of the forward-looking statements included in this
press release. Any forward-looking statement included in this press
release speaks only as of the date on which it was made. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise, except as required by law.
Investor and
Media Contact:Carl MauchSenior
Director, Investor Relations and Corporate Communications (617)
949-5667carl.mauch@tcr2.com
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024